Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment. Real-world studies show that UZEDY (risperidone), a long-acting injectable suspension administered subcutaneously every one or two months, delivers better outcomes compared to daily oral antipsychotics.

Teva Pharmaceutical Industries Limited (TEVA) Highlights Long-Acting Injectable Advancements for Schizophrenia at 2025 Psych Congress

A medical professional discussing the prescription-only therapy with a patient.

Patients on UZEDY experienced lower relapse rates (9.0% vs. 15.4% for second-generation oral antipsychotics), longer time to relapse, improved adherence (71.3% vs. 52.8%), and greater treatment persistence. UZEDY users also had fewer inpatient, outpatient, and emergency department visits, shorter hospital stays, and reduced overall healthcare costs.

Additionally, Teva Pharmaceutical Industries Limited presented Phase 3 SOLARIS trial results for TEV-‘749, an investigational once-monthly subcutaneous olanzapine formulation. After more than 3,400 injections, there were no suspected or confirmed cases of post-injection delirium/sedation syndrome (PDSS), a key safety concern with existing olanzapine injectables. The safety profile of TEV-‘749 aligned with approved olanzapine options, and the drug met its primary efficacy endpoint across all dosing groups.

These findings reinforce Teva Pharmaceutical Industries Limited’s leadership in developing innovative, long-acting schizophrenia therapies designed to improve patient outcomes and address critical gaps in current treatment options.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.